Tags

Type your tag names separated by a space and hit enter

Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma.
Invest Ophthalmol Vis Sci. 2009 Dec; 50(12):5800-4.IO

Abstract

PURPOSE

To investigate the neuroprotective effect of candesartan, an angiotensin II type 1 receptor (AT1-R) blocker, against the neurotoxicity of the retinal ganglion cells (RGCs) in an animal model of glaucoma.

METHODS

Cauterization of three episcleral vessels in rats was used to create chronically elevated intraocular pressure (IOP) in one eye. Rats were then treated orally with candesartan (1 mg/kg/d). At 10 weeks, immunohistochemistry was used for quantification of RGC survival and examination of retinal localization of AT1-R.

RESULTS

Compared with the contralateral control eyes, there was a consistently elevated IOP of approximately 2.5-fold during the experimental period. At the end of the 10-week candesartan treatment, there were no changes noted for the blood pressure. Compared with the contralateral control eyes that had normal IOP, the RGC survival rate in the central retina of eyes with the chronic, elevated IOP was 46.5% +/- 19.4% (mean +/- SD) in the untreated animals and 84.2% +/- 4.9% in the candesartan-treated animals (P < 0.05; unpaired t-test). In the retina of the normal IOP rat eyes, retinal vessels were positive for AT1-R. After 10 weeks of IOP elevation, immunohistochemical analysis of the retina indicated there were many AT1-R-positive RGCs in the candesartan-treated rat, whereas there was an apparent AT1-R decrease in the vehicle-treated rats.

CONCLUSIONS

In the rat chronic glaucoma model, continuous pharmacologic treatment using candesartan results in significant neuroprotection against RGC loss.

Authors+Show Affiliations

Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19608537

Citation

Yang, Hongwei, et al. "Neuroprotective Effects of Angiotensin II Type 1 Receptor Blocker in a Rat Model of Chronic Glaucoma." Investigative Ophthalmology & Visual Science, vol. 50, no. 12, 2009, pp. 5800-4.
Yang H, Hirooka K, Fukuda K, et al. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest Ophthalmol Vis Sci. 2009;50(12):5800-4.
Yang, H., Hirooka, K., Fukuda, K., & Shiraga, F. (2009). Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Investigative Ophthalmology & Visual Science, 50(12), 5800-4. https://doi.org/10.1167/iovs.09-3678
Yang H, et al. Neuroprotective Effects of Angiotensin II Type 1 Receptor Blocker in a Rat Model of Chronic Glaucoma. Invest Ophthalmol Vis Sci. 2009;50(12):5800-4. PubMed PMID: 19608537.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. AU - Yang,Hongwei, AU - Hirooka,Kazuyuki, AU - Fukuda,Kouki, AU - Shiraga,Fumio, Y1 - 2009/07/15/ PY - 2009/7/18/entrez PY - 2009/7/18/pubmed PY - 2009/12/24/medline SP - 5800 EP - 4 JF - Investigative ophthalmology & visual science JO - Invest Ophthalmol Vis Sci VL - 50 IS - 12 N2 - PURPOSE: To investigate the neuroprotective effect of candesartan, an angiotensin II type 1 receptor (AT1-R) blocker, against the neurotoxicity of the retinal ganglion cells (RGCs) in an animal model of glaucoma. METHODS: Cauterization of three episcleral vessels in rats was used to create chronically elevated intraocular pressure (IOP) in one eye. Rats were then treated orally with candesartan (1 mg/kg/d). At 10 weeks, immunohistochemistry was used for quantification of RGC survival and examination of retinal localization of AT1-R. RESULTS: Compared with the contralateral control eyes, there was a consistently elevated IOP of approximately 2.5-fold during the experimental period. At the end of the 10-week candesartan treatment, there were no changes noted for the blood pressure. Compared with the contralateral control eyes that had normal IOP, the RGC survival rate in the central retina of eyes with the chronic, elevated IOP was 46.5% +/- 19.4% (mean +/- SD) in the untreated animals and 84.2% +/- 4.9% in the candesartan-treated animals (P < 0.05; unpaired t-test). In the retina of the normal IOP rat eyes, retinal vessels were positive for AT1-R. After 10 weeks of IOP elevation, immunohistochemical analysis of the retina indicated there were many AT1-R-positive RGCs in the candesartan-treated rat, whereas there was an apparent AT1-R decrease in the vehicle-treated rats. CONCLUSIONS: In the rat chronic glaucoma model, continuous pharmacologic treatment using candesartan results in significant neuroprotection against RGC loss. SN - 1552-5783 UR - https://www.unboundmedicine.com/medline/citation/19608537/Neuroprotective_effects_of_angiotensin_II_type_1_receptor_blocker_in_a_rat_model_of_chronic_glaucoma_ L2 - https://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.09-3678 DB - PRIME DP - Unbound Medicine ER -